(PGNX) |
| 0 (0%) 11-27 10:03 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.83 |
| Resistance 1: | 4.31 |
| Pivot price: | 4.35 |
| Support 1: | 3.48 |
| Support 2: | 2.90 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -0.774 |
| Book Value | 0.350 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.367 |
| Profit Margin (%) | -180.28 |
| Operating Margin (%) | -165.87 |
| Return on Assets (ttm) | -29.2 |
| Return on Equity (ttm) | -116.9 |
Company news
Thu, 25 Jul 2019
Progenics Pharmaceuticals Announces Collaboration with - GlobeNewswire
Wed, 17 Jul 2019
Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets - PR Newswire
Thu, 14 Mar 2019
Progenics Asserts Ownership of PSMA-617 Intellectual Property, Including Composition of Matter Patent - GlobeNewswire
Thu, 03 Jan 2019
Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™ - GlobeNewswire
Mon, 02 May 2016
Progenics Licenses PSMA Antibody Technology to Bayer for - GlobeNewswire
Tue, 22 Jul 2014
Kevin Kotler, Broadfin Capital Increase Holding Of Progenics Pharmaceuticals, Inc. (PGNX) - Insider Monkey
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
